US Pharma MarketingFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report…
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen’s Tazverik from the U.S. market.
Source: FierceBiotech